Incontinence News and Research

Latest Incontinence News and Research

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

UK's NICE issues guidance on PTNS treatment for faecal incontinence

Uroplasty, Inc., announced today that the United Kingdom's National Institute for Health and Clinical Excellence issued guidance on percutaneous tibial nerve stimulation for the treatment of faecal incontinence.

31 May 2011

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed.

30 May 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011

Loss of elasticity and protein breakdown cause pelvic organ prolapse

A gynecologist and a molecular biologist at UT Southwestern Medical Center have collaborated to show for the first time that pelvic organ prolapse - a condition in which the uterus, bladder or vagina protrude from the body - is caused by a combination of a loss of elasticity and a breakdown of proteins in the vaginal wall.

24 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

AMS signs research grant contract for six sites to evaluate vaginal prolapse repair techniques

American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.

13 May 2011

Mesh surgery more effective for patients with pelvic organ prolapse

A Nordic multicentre study, headed by researchers from Karolinska Institutet in Sweden, shows that pelvic organ prolapse surgery using synthetic mesh can be more effective than traditional surgery.

12 May 2011

Surgery reduces mortality risk of prostate cancer

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

6 May 2011

Caldera's Desara Mini implant for Stress Urinary Incontinence receives CE Mark certification

Caldera Medical today announced that it has achieved CE Mark certification for its Desara Mini implant, an extension of its popular Desara brand for the treatment of Stress Urinary Incontinence.

6 May 2011

Devrom is effective for eliminating flatulence, stool odor issues

Flatulence. Everyone has it. Common factors contributing to flatus production are swallowed air and digestion of certain foods in the intestine. Perhaps one of the most embarrassing aspects of flatulence is the smelly odor, but there is a remedy and it is called Devrom.

5 May 2011

SRS Medical announces pelvic health program for women

SRS Medical today announced the formation of Restore Continence™, a women's pelvic health program based on the use of a comprehensive suite of medical devices for diagnosing and treating urinary incontinence.

3 May 2011

Simbionix to exhibit new training simulator for pelvic floor repair at ACOG

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.

3 May 2011

USHIFU announces results from clinical investigation of Sonablate HIFU to treat prostate cancer

USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.

30 Apr 2011

Uroplasty to present Urgent PC, Macroplastique products study data at upcoming meetings

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent PC Neuromodulation System and Macroplastique urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.

25 Apr 2011

Urologic Nursing publishes NAFC nocturia research in middle-aged American women

Research by the National Association For Continence about nocturia in middle-aged American women appears in the current issue of Urologic Nursing, the official journal of the Society of Urologic Nurses and Associates.

22 Apr 2011

Physiotherapy Associates inaugurates new clinic in Grand Haven, MI

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.

22 Apr 2011

Endo Pharmaceuticals to acquire American Medical Systems

Endo Pharmaceuticals and American Medical Systems today that they have entered into a definitive agreement under which Endo will acquire AMS, a leading provider of world-class devices and therapies for male and female pelvic health, for $30 per share, or $2.9 billion in cash, which includes the assumption and repayment of $312 million of AMS debt.

11 Apr 2011

NHIC to cover PTNS using Uroplasty's Urgent PC Neuromodulation System for overactive bladder

Uroplasty, Inc. announced that NHIC Corp., the Medicare carrier for Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont, will cover posterior tibial nerve stimulation (PTNS) using Uroplasty's Urgent® PC Neuromodulation System for the treatment of overactive bladder and associated symptoms, effective May 22, 2011.

8 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011